Lonza loads up $5.5bn funding for Capsugel buy
Swiss pharmaceutical and biotech ingredients supplier Lonza has secured $5.5bn in funds from Bank of America Merrill Lynch and UBS for the acquisition of US dosage form maker Capsugel, in a financing package that includes a variety of debt and equity products.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: